STAT June 21, 2024
Adam Feuerstein

Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration expanded approval of the company’s Duchenne muscular dystrophy drug on Thursday. Will boys with Duchenne also benefit? I hope they do, but it’s uncertain. And is this a good look for the FDA? No, it is not.

There is much to unpack from the unilateral decision by Peter Marks, the FDA’s top regulator of gene...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
New AI model predicts gene expression across human cell types
Measuring Progress for Life Sciences: Trust, Patient Access, and Prevention at a Fork in the Road of Public Health
2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies
Christophe Weber, veteran Takeda CEO, to retire next year
Walmart To Expand Same-Day Prescription Delivery Nationwide

Share This Article